Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$25.50 USD
+0.84 (3.41%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $25.52 +0.02 (0.08%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Amphastar Pharmaceuticals, Inc. has a PEG ratio of 4.49 compared to the Medical - Generic Drugs industry's PEG ratio of 5.07.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AMPH 25.50 +0.84(3.41%)
Will AMPH be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for AMPH based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for AMPH
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?
AMPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Down 15.4% in 4 Weeks, Here's Why Amphastar (AMPH) Looks Ripe for a Turnaround
Other News for AMPH
AMPH forms 20 Day Moving Average Support on October 31
Is AMPH primed for upward momentum? Crossed Above 20 Day Moving Average shows up after advancing 1.73%
AMPH forms 20 Day Moving Average Resistance on October 29
AMPH's price rises by 0.58% on October 28, though its technical setup remains stable.
The technical outlook for AMPH is unchanged after it falls 1.96% on October 27